Assembly Biosciences Inc (ASMB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $24.97 (-1.46%), Market cap $0.43B, P/E ratio 335.19, 52-week low–high $13.52 ~ $38.50.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7
Financial statements, price targets, institutional (13F) holdings and related news for Assembly Biosciences Inc are updated in real time on BlackAll Trade.
Assembly Biosciences Inc trades at $24.97 (-1.46%). Real-time quotes and charts are available on BlackAll Trade.
Assembly Biosciences Inc has a market cap of about $0.43B. Its P/E ratio is 335.19.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candid